viloxazine

Adjunctive therapy • Brands: Qelbree

Last reviewed: 2026-02-23

General information

Class: Adjunctive therapy
Common US brands: Qelbree
Typical dose range: Pediatric ages 6–11: start 100 mg once daily; titrate by 100 mg weekly to a maximum of 400 mg once daily (label).
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2026-02-23

Dosing & forms

Forms/strengths: Extended-release capsules: 100 mg, 150 mg, 200 mg (label).; Capsules may be swallowed whole or opened and sprinkled onto applesauce or pudding (label).
Frequency: Pediatric ages 6–11: start 100 mg once daily; titrate by 100 mg weekly to a maximum of 400 mg once daily (label).
Typical range: Pediatric ages 6–11: start 100 mg once daily; titrate by 100 mg weekly to a maximum of 400 mg once daily (label).

Mechanism (brief)

Nonstimulant ADHD medication (viloxazine extended-release) that modulates norepinephrine signaling; carries a boxed warning for suicidal thoughts/behaviors and is a strong CYP1A2 inhibitor with clinically important drug interactions.

Metabolism & Half‑life

Metabolism: CYP2D6, UGT1A9, UGT2B15
Half‑life: Single-dose mean 7 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Monitoring highlights

Suicidal thoughts and behaviors monitoring during initiation and dose changes (boxed warning; label).
Blood pressure and heart rate assessment at baseline, after dose increases, and periodically (label).
Appetite/weight and sleep monitoring, especially in pediatric patients (clinical).
Drug interaction review focused on CYP1A2 substrates and narrow-therapeutic-range agents (label).

Sources

QELBREE (viloxazine) extended-release capsules prescribing information — DailyMed (2025)
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents — Pediatrics (2019)
Attention deficit hyperactivity disorder (NICE guideline NG87) — NICE (2018)
Comparative efficacy and tolerability of medications for ADHD (systematic review and network meta-analysis) — Lancet Psychiatry (2018)

Dosing & forms

Forms/strengths: Extended-release capsules: 100 mg, 150 mg, 200 mg (label).; Capsules may be swallowed whole or opened and sprinkled onto applesauce or pudding (label).

Frequency: Pediatric ages 6–11: start 100 mg once daily; titrate by 100 mg weekly to a maximum of 400 mg once daily (label).

Typical range: Pediatric ages 6–11: start 100 mg once daily; titrate by 100 mg weekly to a maximum of 400 mg once daily (label).

Monitoring highlights

Suicidal thoughts and behaviors monitoring during initiation and dose changes (boxed warning; label).

Blood pressure and heart rate assessment at baseline, after dose increases, and periodically (label).

Appetite/weight and sleep monitoring, especially in pediatric patients (clinical).

Drug interaction review focused on CYP1A2 substrates and narrow-therapeutic-range agents (label).